Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia

Aims Mipomersen, an apolipoprotein (apo) B synthesis inhibitor, has been shown to produce potent reductions in apoB and LDL-cholesterol levels in animal models as well as healthy human volunteers. A randomized, double-blind, placebo-controlled, dose-escalation study was designed to evaluate the efficacy and safety of mipomersen monotherapy with or without dose loading in subjects with mild-to-moderate hyperlipidaemia. Methods and results Fifty subjects with LDL-cholesterol levels between 119 and 266 mg/dL were enrolled into five cohorts at a 4:1 randomization ratio of active to placebo. Two 13-week dose regimens were evaluated at doses ranging from 50 to 400 mg/week. Mipomersen produced dose-dependent reductions in all apoB containing lipoproteins. In the 200 and 300 mg/week dose cohorts, mean reductions from baseline in LDL cholesterol were −45 ± 10% ( P = 0.000) and −61 ± 8% ( P = 0.000), corresponding to a −46 ± 11% ( P = 0.000) and −61 ± 7% ( P = 0.000) decrease in apoB levels. Triglyceride levels were also lowered with median reductions up to 53% ( P = 0.021). The most common adverse events were injection site reactions. Seven of 40 subjects (18%) showed consecutive trans -aminase elevations >3× upper limit of normal. Five of these subjects received 400 mg/week, four of whom had apoB levels below the limit of detection. As a consequence, the 400 mg/week cohort was discontinued. Conclusions Mipomersen administered as monotherapy in subjects with mild-to-moderate hyperlipidaemia produced potent reductions in all apoB-containing lipoproteins. Higher doses were associated with hepatic trans -aminase increases. This trial is registered at clinicaltrials.gov as [NCT00216463][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00216463&atom=%2Fehj%2Fearly%2F2011%2F05%2F18%2Feurheartj.ehr148.atom